138 results
Page 2 of 7
8-K
EX-99.1
p6zjn 36vyjcw
4 May 23
Intra-cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
jpfpxtm8pe5 owzu
3 Nov 22
Intra-cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:35am
8-K
EX-99.1
rq99czu x6rrhj
9 Aug 22
Intra-cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:38am
8-K
EX-99.1
9szm53y52o 3ux71z669
10 May 22
Intra-cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
vf0kehi
25 Apr 22
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
7:12am
8-K
EX-99.1
4dellntq3h8rt2
1 Mar 22
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2021 Financial Results and Provides Corporate Update
7:49am
8-K
EX-1.1
hp6jq9r5pmgjw4q75of2
5 Jan 22
Entry into a Material Definitive Agreement
5:06pm
424B5
futkq6l
5 Jan 22
Prospectus supplement for primary offering
4:51pm
8-K
EX-99.2
niz56prjder4tdr4d5
4 Jan 22
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
12:00am
424B5
uxg4gj8xzl 7q
3 Jan 22
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
6muw7x0
20 Dec 21
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
7:04am